Monday, June 14, 2021 4:05:16 PM
Recent RAPT News
- RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients • GlobeNewswire Inc. • 04/09/2024 04:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:15:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 01:08:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:03:10 PM
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 10:13:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:29:38 PM
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon • GlobeNewswire Inc. • 02/20/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:52:45 PM
- RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations • GlobeNewswire Inc. • 02/13/2024 01:00:00 PM
- RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:08:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:08 PM
- RAPT Therapeutics Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 04:03:08 PM
- RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November • GlobeNewswire Inc. • 11/01/2023 08:05:00 PM
- RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
- RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September • GlobeNewswire Inc. • 08/30/2023 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/18/2023 04:15:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:02:58 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM